Greenwich LifeSciences Competitors

Johnson & Johnson (NYSE:JNJ) and Greenwich LifeSciences (NASDAQ:GLSI) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, valuation, risk, dividends and analyst recommendations.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Johnson & Johnson and Greenwich LifeSciences, as provided by MarketBeat.com.

Johnson & Johnson presently has a consensus target price of $185.70, indicating a potential upside of 9.06%. Greenwich LifeSciences has a consensus target price of $75.00, indicating a potential upside of 140.08%. Given Greenwich LifeSciences' stronger consensus rating and higher possible upside, analysts plainly believe Greenwich LifeSciences is more favorable than Johnson & Johnson.

Earnings & Valuation

This table compares Johnson & Johnson and Greenwich LifeSciences' revenue, earnings per share (EPS) and valuation.

Johnson & Johnson has higher revenue and earnings than Greenwich LifeSciences.

Insider & Institutional Ownership

67.3% of Johnson & Johnson shares are held by institutional investors. 0.3% of Johnson & Johnson shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares Johnson & Johnson and Greenwich LifeSciences' net margins, return on equity and return on assets.

Summary

Johnson & Johnson beats Greenwich LifeSciences on 7 of the 9 factors compared between the two stocks.

Greenwich LifeSciences (NASDAQ:GLSI) and Pfizer (NYSE:PFE) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, risk, profitability, earnings and analyst recommendations.

Analyst Ratings

This is a breakdown of recent recommendations for Greenwich LifeSciences and Pfizer, as provided by MarketBeat.

Greenwich LifeSciences presently has a consensus target price of $75.00, indicating a potential upside of 140.08%. Pfizer has a consensus target price of $39.6429, indicating a potential downside of 0.54%. Given Greenwich LifeSciences' stronger consensus rating and higher possible upside, equities research analysts clearly believe Greenwich LifeSciences is more favorable than Pfizer.

Valuation & Earnings

This table compares Greenwich LifeSciences and Pfizer's top-line revenue, earnings per share (EPS) and valuation.

Pfizer has higher revenue and earnings than Greenwich LifeSciences.

Insider and Institutional Ownership

67.4% of Pfizer shares are held by institutional investors. 0.1% of Pfizer shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Greenwich LifeSciences and Pfizer's net margins, return on equity and return on assets.

Summary

Pfizer beats Greenwich LifeSciences on 7 of the 9 factors compared between the two stocks.

Greenwich LifeSciences (NASDAQ:GLSI) and Abbott Laboratories (NYSE:ABT) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, risk, profitability, earnings and analyst recommendations.

Analyst Ratings

This is a breakdown of recent recommendations for Greenwich LifeSciences and Abbott Laboratories, as provided by MarketBeat.

Greenwich LifeSciences presently has a consensus target price of $75.00, indicating a potential upside of 140.08%. Abbott Laboratories has a consensus target price of $125.8125, indicating a potential upside of 5.78%. Given Greenwich LifeSciences' stronger consensus rating and higher possible upside, equities research analysts clearly believe Greenwich LifeSciences is more favorable than Abbott Laboratories.

Valuation & Earnings

This table compares Greenwich LifeSciences and Abbott Laboratories' top-line revenue, earnings per share (EPS) and valuation.

Abbott Laboratories has higher revenue and earnings than Greenwich LifeSciences.

Insider and Institutional Ownership

72.6% of Abbott Laboratories shares are held by institutional investors. 1.7% of Abbott Laboratories shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Greenwich LifeSciences and Abbott Laboratories' net margins, return on equity and return on assets.

Summary

Abbott Laboratories beats Greenwich LifeSciences on 7 of the 9 factors compared between the two stocks.

Greenwich LifeSciences (NASDAQ:GLSI) and AbbVie (NYSE:ABBV) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, risk, profitability, earnings and analyst recommendations.

Analyst Ratings

This is a breakdown of recent recommendations for Greenwich LifeSciences and AbbVie, as provided by MarketBeat.

Greenwich LifeSciences presently has a consensus target price of $75.00, indicating a potential upside of 140.08%. AbbVie has a consensus target price of $117.1250, indicating a potential upside of 0.78%. Given Greenwich LifeSciences' stronger consensus rating and higher possible upside, equities research analysts clearly believe Greenwich LifeSciences is more favorable than AbbVie.

Valuation & Earnings

This table compares Greenwich LifeSciences and AbbVie's top-line revenue, earnings per share (EPS) and valuation.

AbbVie has higher revenue and earnings than Greenwich LifeSciences.

Insider and Institutional Ownership

67.5% of AbbVie shares are held by institutional investors. 0.1% of AbbVie shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Greenwich LifeSciences and AbbVie's net margins, return on equity and return on assets.

Summary

AbbVie beats Greenwich LifeSciences on 7 of the 9 factors compared between the two stocks.

Greenwich LifeSciences (NASDAQ:GLSI) and Novartis (NYSE:NVS) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, risk, profitability, earnings and analyst recommendations.

Analyst Ratings

This is a breakdown of recent recommendations for Greenwich LifeSciences and Novartis, as provided by MarketBeat.

Greenwich LifeSciences presently has a consensus target price of $75.00, indicating a potential upside of 140.08%. Novartis has a consensus target price of $108.50, indicating a potential upside of 23.32%. Given Greenwich LifeSciences' stronger consensus rating and higher possible upside, equities research analysts clearly believe Greenwich LifeSciences is more favorable than Novartis.

Valuation & Earnings

This table compares Greenwich LifeSciences and Novartis' top-line revenue, earnings per share (EPS) and valuation.

Novartis has higher revenue and earnings than Greenwich LifeSciences.

Insider and Institutional Ownership

9.9% of Novartis shares are held by institutional investors. 0.0% of Novartis shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Greenwich LifeSciences and Novartis' net margins, return on equity and return on assets.

Summary

Novartis beats Greenwich LifeSciences on 7 of the 9 factors compared between the two stocks.

Merck & Co., Inc. (NYSE:MRK) and Greenwich LifeSciences (NASDAQ:GLSI) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, earnings, institutional ownership, risk, dividends and valuation.

Analyst Ratings

This is a summary of current ratings for Merck & Co., Inc. and Greenwich LifeSciences, as reported by MarketBeat.com.

Merck & Co., Inc. currently has a consensus price target of $97.50, indicating a potential upside of 24.73%. Greenwich LifeSciences has a consensus price target of $75.00, indicating a potential upside of 140.08%. Given Greenwich LifeSciences' stronger consensus rating and higher possible upside, analysts plainly believe Greenwich LifeSciences is more favorable than Merck & Co., Inc..

Earnings & Valuation

This table compares Merck & Co., Inc. and Greenwich LifeSciences' top-line revenue, earnings per share and valuation.

Merck & Co., Inc. has higher revenue and earnings than Greenwich LifeSciences.

Insider and Institutional Ownership

72.9% of Merck & Co., Inc. shares are held by institutional investors. 0.3% of Merck & Co., Inc. shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Merck & Co., Inc. and Greenwich LifeSciences' net margins, return on equity and return on assets.

Summary

Merck & Co., Inc. beats Greenwich LifeSciences on 7 of the 9 factors compared between the two stocks.